On Tuesday, NovoCure Ltd (NASDAQ: NVCR) opened lower -0.11% from the last session, before settling in for the closing price of $18.31. Price fluctuations for NVCR have ranged from $12.17 to $34.13 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 12.60% annually for the last half of the decade. Company’s average yearly earnings per share was noted -4.67% at the time writing. With a float of $99.75 million, this company’s outstanding shares have now reached $111.48 million.
In an organization with 1488 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 77.16%, operating margin of -26.84%, and the pretax margin is -20.88%.
NovoCure Ltd (NVCR) Insider Updates
A key investor’s attitude towards the stock of the Medical Devices industry is another important factor to consider. The insider ownership of NovoCure Ltd is 10.53%, while institutional ownership is 85.02%. The most recent insider transaction that took place on Mar 03 ’25, was worth 5,071. In this transaction Chief Innovation Officer of this company sold 268 shares at a rate of $18.92, taking the stock ownership to the 166,243 shares. Before that another transaction happened on Mar 03 ’25, when Company’s EVP, Pres., Novocure Oncology sold 2,527 for $18.54, making the entire transaction worth $46,841. This insider now owns 143,673 shares in total.
NovoCure Ltd (NVCR) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.43 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -4.67% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 8.26% during the next five years compared to -83.87% drop over the previous five years of trading.
NovoCure Ltd (NASDAQ: NVCR) Trading Performance Indicators
Check out the current performance indicators for NovoCure Ltd (NVCR). In the past quarter, the stock posted a quick ratio of 1.41. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.28.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.51, a number that is poised to hit -0.38 in the next quarter and is forecasted to reach -1.75 in one year’s time.
Technical Analysis of NovoCure Ltd (NVCR)
Let’s dig in a bit further. During the last 5-days, its volume was 1.13 million. That was better than the volume of 0.91 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 78.01%. Additionally, its Average True Range was 1.06.
During the past 100 days, NovoCure Ltd’s (NVCR) raw stochastic average was set at 18.01%, which indicates a significant decrease from 78.47% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 64.42% in the past 14 days, which was higher than the 57.59% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $18.70, while its 200-day Moving Average is $20.40. However, in the short run, NovoCure Ltd’s stock first resistance to watch stands at $18.65. Second resistance stands at $19.01. The third major resistance level sits at $19.49. If the price goes on to break the first support level at $17.81, it is likely to go to the next support level at $17.32. Assuming the price breaks the second support level, the third support level stands at $16.96.
NovoCure Ltd (NASDAQ: NVCR) Key Stats
There are currently 111,486K shares outstanding in the company with a market cap of 2.04 billion. Presently, the company’s annual sales total 605,220 K according to its annual income of -168,630 K. Last quarter, the company’s sales amounted to 154,990 K and its income totaled -34,320 K.
